XOMA Royalty (XOMA) Shares Outstanding (Diluted Average) (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Shares Outstanding (Diluted Average) came in at $17.4 million in Q1 2026, down 2.05% year-on-year from $17.8 million in Q1 2025, and down 3.14% quarter-over-quarter from $18.0 million in Q4 2025.
XOMA Royalty (XOMA) Shares Outstanding (Diluted Average) (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Shares Outstanding (Diluted Average) across 16 years of filings, most recently posting $17.4 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $17.4 million, down 2.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.4 million (down 2.05% YoY), and the FY2025 annual result was $18.0 million, up 53.68% from the prior year.
- Shares Outstanding (Diluted Average) came in at $17.4 million for Q1 2026 at XOMA Royalty, down from $18.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $18.1 million in Q3 2025 to a low of $11330.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $11.7 million (2024), against an average of $11.0 million.
- Across the five-year window, Shares Outstanding (Diluted Average) slumped 99.9% in 2022 and soared 100947.12% in 2024, its largest moves.
- XOMA Royalty's Shares Outstanding (Diluted Average) stood at $11400.0 in 2022, then surged by 100540.35% to $11.5 million in 2023, then rose by 1.99% to $11.7 million in 2024, then surged by 53.68% to $18.0 million in 2025, then dropped by 3.14% to $17.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $17.4 million (Q1 2026), $18.0 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 17.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.42 Mn |
| Dec 31, 2025 | 17.98 Mn |
| Sep 30, 2025 | 18.14 Mn |
| Jun 30, 2025 | 17.78 Mn |
| Mar 31, 2025 | 17.78 Mn |
| Dec 31, 2024 | 11.70 Mn |
| Sep 30, 2024 | 11.71 Mn |
| Jun 30, 2024 | 17.32 Mn |
| Mar 31, 2024 | 11.58 Mn |
| Sep 30, 2023 | 11.47 Mn |
| Jun 30, 2023 | 11.46 Mn |
| Mar 31, 2023 | 11,460.00 |
| Sep 30, 2022 | 11,400.00 |
| Jun 30, 2022 | 11,376.00 |
| Mar 31, 2022 | 11,330.00 |
| Sep 30, 2021 | 11.31 Mn |
| Jun 30, 2021 | 11.26 Mn |
| Mar 31, 2021 | 11.24 Mn |
| Sep 30, 2020 | 10.54 Mn |
| Mar 31, 2020 | 9.76 Mn |